M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Survey of Parent/Caregiver Practices on the Storage, Use, and Disposal of Opioids in a Comprehensive Cancer Center

Completed

Conditions: Malignant Neoplasm
Caregiver

Interventions: Other: Survey Administration

First Posted Date: 2018-01-04

Last Posted Date: 2023-11-21

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 115

Registration Number: NCT03390283

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome

Phase 2

Recruiting

Conditions: Acute Myeloid Leukemia
Blasts 20-30 Percent of Bone Marrow Nucleated Cells
Chronic Myelomonocytic Leukemia
IDH2 Gene Mutation
Myelodysplastic Syndrome With Excess Blasts
Recurrent High Risk Myelodysplastic Syndrome
Refractory High Risk Myelodysplastic Syndrome

Interventions: Drug: Azacitidine
Drug: Enasidenib
Other: Quality-of-Life Assessment

First Posted Date: 2017-12-26

Last Posted Date: 2025-02-10

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 63

Registration Number: NCT03383575

Locations: 🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸
Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Cabozantinib in Treating Patients With Locally Advanced or Metastatic Unresectable Adrenocortical Carcinoma

Phase 2

Completed

Conditions: Metastatic Carcinoma in the Adrenal Cortex
Stage III Adrenal Cortex Carcinoma AJCC v8
Stage IV Adrenal Cortex Carcinoma AJCC v8
Unresectable Adrenal Cortex Carcinoma

Interventions: Drug: Cabozantinib
Other: Pharmacogenomic Study
Other: Pharmacokinetic Study

First Posted Date: 2017-12-12

Last Posted Date: 2024-12-10

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 18

Registration Number: NCT03370718

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Dexamethasone in Controlling Dyspnea in Patients With Cancer

Phase 2

Active, not recruiting

Conditions: Dyspnea
Malignant Neoplasm

Interventions: Drug: Dexamethasone
Other: Questionnaire Administration
Other: Placebo

First Posted Date: 2017-12-08

Last Posted Date: 2025-05-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 135

Registration Number: NCT03367156

Locations: 🇺🇸
Lyndon B. Johnson Hospital, Houston, Texas, United States
🇺🇸
Harris Health System Settegast Health Center, Houston, Texas, United States
🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer

Phase 2

Active, not recruiting

Conditions: Castration-Resistant Prostate Carcinoma
Prostate Adenocarcinoma Without Neuroendocrine Differentiation
Stage IV Prostate Cancer AJCC v8
Stage IVA Prostate Cancer AJCC v8
Stage IVB Prostate Cancer AJCC v8

Interventions: Drug: Abiraterone Acetate
Drug: Apalutamide
Drug: Prednisone

First Posted Date: 2017-12-04

Last Posted Date: 2025-03-10

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 7

Registration Number: NCT03360721

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Questionnaires in Assessing Attitudes About Legalization of Marijuana Use in Participants With Cancer

Completed

Conditions: Malignant Neoplasm

Interventions: Other: Questionnaire Administration

First Posted Date: 2017-12-04

Last Posted Date: 2019-08-30

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 103

Registration Number: NCT03360799

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States

Four Quadrants Transverse Abdominus Plane (4Q-TAP) Block With Plain and Liposomal Bupivacaine vs. Thoracic Epidermal Analgesia (TEA) in Patients Undergoing Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy (CRS-HIPEC) on an Enhanced Recovery Pathway

Phase 3

Completed

Conditions: Peritoneal Cancer

Interventions: Drug: Local Anesthetic Solution
Drug: Bupivacaine HCl
Drug: Liposomal Bupivacaine

First Posted Date: 2017-12-02

Last Posted Date: 2022-02-18

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 75

Registration Number: NCT03359811

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Radiation Therapy Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Breast Cancer

Phase 2

Active, not recruiting

Conditions: Invasive Breast Carcinoma
Estrogen Receptor Positive
HER2/Neu Negative
Progesterone Receptor Positive

Interventions: Radiation: Radiation Therapy
Procedure: Therapeutic Conventional Surgery

First Posted Date: 2017-12-02

Last Posted Date: 2025-04-27

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 25

Registration Number: NCT03359954

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Study of Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology

Phase 1

Completed

Conditions: Diseases of Oesophagus Stomach and Duodenum

Interventions: Drug: Dexamethasone
Drug: Diphenhydramine
Drug: Famotidine
Drug: Mitomycin C
Drug: Cisplatin
Drug: Paclitaxel

First Posted Date: 2017-11-06

Last Posted Date: 2023-04-21

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 29

Registration Number: NCT03330028

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Effectiveness of Bronchoscopic Interventions for Malignant Airway Obstruction

Completed

Conditions: Lung Cancer

Interventions: Behavioral: Medical Data Collection

First Posted Date: 2017-10-31

Last Posted Date: 2019-04-16

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 110

Registration Number: NCT03326570

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy